sprite-preloader
Anzeige
Mehr »
Dienstag, 23.04.2019 Börsentäglich über 12.000 News von 604 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2JAZX ISIN: SE0006371126 Ticker-Symbol: 7V3 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
1-Woche-Intraday-Chart
CANTARGIA AB 1-Woche-Intraday-Chart

Aktuelle News zu CANTARGIA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
DoCantargia Phase I Clinical Results on the Antibody CAN04 Selected for Oral Presentation at ASCO2
STOCKHOLM, April 18, 2019 /PRNewswire/ -- Cantargia AB today announce that the phase I clinical data generated by the antibody CAN04 will be presented orally at the 2019 Annual ASCO meeting...
► Artikel lesen
21.03.Cantargia Makes a Directed Share Issue of Approximately SEK 106 Million for Increased Investments in the Clinical Development of CAN045
STOCKHOLM, March 21, 2019 /PRNewswire/ -- The board of directors of Cantargia AB (publ) has resolved, pursuant to the general meeting's authorization, on a directed share issue of approximately...
► Artikel lesen
CANTARGIA Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!

► Artikel lesen
08.03.Cantargia - Signs of growing interest in IL-1 pathway targets2
Edison Investment Research - Pharmaceuticals & healthcare - Cantargia: In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing...
► Artikel lesen
27.02.Cantargia Publishes Year end Report for 20182
STOCKHOLM, Feb. 27, 2019 /PRNewswire/ --Cantargia AB's ("Cantargia") year end report for 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant...
► Artikel lesen
25.01.Cantargia: First Patient Treated With Antibody CAN04 in the Phase IIa Part of CANFOUR Trial5
STOCKHOLM, Jan. 25, 2019 /PRNewswire/ --Cantargia AB (publ) today announce that the first patient in the phase IIa part of the CANFOUR clinical trial has received CAN04 (nidanilimab) treatment...
► Artikel lesen
03.01.Cantargia - Nidanilimab transitioning to Phase IIa2
Edison Investment Research - Pharmaceuticals & healthcare - Cantargia: On 7 December 2018 Cantargia reached an important milestone - the completion of the Phase I part of its Phase I/IIa CANFOUR study...
► Artikel lesen
10.12.18Cantargia Presents New Positive Preclinical Data on Antibody CAN04 at Major Antibody Conference4
STOCKHOLM, Dec. 10, 2018 /PRNewswire/ --Cantargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference Antibody...
► Artikel lesen
07.12.18Cantargia: Phase I Safety Evaluation Part of CANFOUR Trial of Antibody CAN04 Completed and Phase IIa Part Being Initiated19
STOCKHOLM, Dec 7, 2018 /PRNewswire/ -- Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation...
► Artikel lesen
15.11.18Cantargia Publishes Interim Report for Third Quarter of 20181
STOCKHOLM, Nov. 15, 2018 /PRNewswire/ -- Cantargia AB's interim report for the third quarter of 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant...
► Artikel lesen
30.10.18Cantargia AB: Nomination Committee Appointed Ahead of 2019 Annual General Meeting31
STOCKHOLM, Oct. 30, 2018 /PRNewswire/ -- Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2019 Annual General Meeting, and consists...
► Artikel lesen
20.10.18Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO36
STOCKHOLM, Oct. 20, 2018 /PRNewswire/ -- The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease...
► Artikel lesen
09.10.18Cantargia Presents Clinical Data From its Ongoing CANFOUR Trial at ESMO50
STOCKHOLM, Oct. 9, 2018 /PRNewswire/ -- Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented...
► Artikel lesen
01.10.18Cantargia Obtains Patent in USA for the Antibody CAN034
STOCKHOLM, Oct. 1, 2018 /PRNewswire/ -- Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company's patent application 15/501,710 directed...
► Artikel lesen
25.09.18Nasdaq Nordic: Nasdaq Stockholm Welcomes Cantargia to the Main Market3
Stockholm, September 25, 2018 - Nasdaq (Nasdaq: NDAQ) announces that Cantargia AB (short name: CANTA), a small cap company within the health care sector, today will start trading of its shares on the...
► Artikel lesen
20.09.18Nasdaq Stockholm AB: Admission to trading of Cantargia AB (publ) on Nasdaq Stockholm (134/18)5
On request of Cantargia AB (publ), company registration number 556791-6019, Nasdaq Stockholm AB has admitted the company's shares to trading on Nasdaq Stockholm, with effect from September 25, 2018....
► Artikel lesen
20.09.18Nasdaq Stockholm AB: Last day of trading in Cantargia AB (publ) (341/18)4
At the request of Cantargia AB (publ), the trading in the company's shares on Nasdaq First North premier is to cease. As from September 25, 2018, the shares will be listed on Nasdaq Stockholm. The...
► Artikel lesen
19.09.18Cantargia Publishes Prospectus in Connection with the List Change to Nasdaq Stockholm's Main Market32
STOCKHOLM, Sept. 19, 2018 /PRNewswire/ -- On 13 September 2018, Cantargia AB (publ) ("Cantargia" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the...
► Artikel lesen
19.09.18Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in Japan3
STOCKHOLM, Sweden, Sept. 19, 2018 /PRNewswire/ -- Cantargia AB announce that the Japanese patent authority, JPO has formally approved the company's patent application of the antibody CAN04...
► Artikel lesen
13.09.18Cantargia Has Been Approved for Listing on the Main Market of Nasdaq Stockholm3
STOCKHOLM, Sept. 13, 2018 /PRNewswire/ -- Nasdaq Stockholm's Listing Committee has approved the admission of Cantargia AB's (publ) ("Cantargia" or the "Company") shares for trading on...
► Artikel lesen
21.08.18Cantargia Publishes Half Year Report3
STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Cantargia AB's half year report for the period January until June 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
CANTARGIA AB-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
EVOTEC21,80-1,98 %Leerverkäufer-Alarm! Irre Bewegung bei SAF-Holland - markanter Aufbau bei Aixtron und Aurelius sowie Evotec und Wacker Chemie - deutlicher Abbau bei Software AG, Zalando und Siltronic sowie Heidelberger Druck, Osram und Leoni - insgesamt 18 Veränderungen!
Hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 16. April Seit geraumer Zeit sind die Aktien deutscher Unternehmen verstärkt ins Visier...
► Artikel lesen
MORPHOSYS86,00-2,05 %Morphosys: Neue Studie bei Erfolgsprojekt - Aktie mit Aufholjagd, Evotec im Visier
Die Aktie von Morphosys hat in den vergangenen Wochen und Monaten nur durchschnittlich performt. Im 52-Wochenvergleich legte der Wert des Biotech-Unternehmens knapp sieben Prozent zu. Die Aktie von...
► Artikel lesen
QIAGEN34,00-1,28 %QIAGEN - Vor Erreichen des Ziels deutliche Kursabschläge

► Artikel lesen
BB BIOTECH59,75-0,33 %Münchener Rück, BB Biotech und Allianz: 3 starke Aktienrückkäufer!
Wenn es um das Thema "Kapitalrückführungen" geht, scheiden sich oft die Geister. Viele Investoren neigen dazu, vor allem auf starke Dividendenausschütter zu setzen. Durch die regelmäßigen Ausschüttungen...
► Artikel lesen
CLINUVEL14,70-6,55 %Clinuvel Pharmaceuticals: Die große Rallye kommt erst noch?
Die Aktie von Clinuvel Pharmaceuticals (WKN: A0JEGY) ist ein Paradebeispiel für Biotech- und Pharmaaktien, die Anlegern fantastische Gewinne bescheren und auch dafür, wie schnell Aktien aus diesem Sektor...
► Artikel lesen
Lade...